Abstract
Acute myelocytic leukemia (AML) is a malignancy that is intrinsically resistant to methotrexate (MTX). AML blasts, when incubated with radiolabeled MTX, form lower amounts of long chain polyglutamates compared to acute lymphocytic leukemia (ALL) blasts, thus providing an explanation for their lack of responsiveness to MTX. Leukemic blasts obtained from two children with acute megakaryocytic leukemia (M7 subtype) when incubated with radiolabeled MTX showed increased accumulation of total as well as long chain MTX polyglutamates, comparable to levels previously demonstrated in another subtype of AML, acute monocytic leukemia (M5), as well as in blasts from patients with pre-B ALL. We suggest that M7-AML patients with blasts showing increased MIX polyglutamylation might benefit from treatment with MTX.
Original language | English (US) |
---|---|
Pages (from-to) | 886-889 |
Number of pages | 4 |
Journal | Leukemia |
Volume | 11 |
Issue number | 6 |
DOIs | |
State | Published - 1997 |
Externally published | Yes |
Keywords
- Acute megakaryocytic leukemia
- Acute myelocytic leukemia
- Methotrexate
- Polyglutamylation
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research